Biblio

Export 50 results:
Author Title Type [ Year(Asc)]
Filters: Author is Blennow, Kaj  [Clear All Filters]
2017
C. L. Russell, Mitra, V., Hansson, K., Blennow, K., Gobom, J., Zetterberg, H., Hiltunen, M., Ward, M., and Pike, I., “Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates.”, J Alzheimers Dis, vol. 55, no. 1, pp. 303-313, 2017.
A. - M. Miller, Balasa, M., Blennow, K., Gardiner, M., Rutkowska, A., Scheltens, P., Teunissen, C. E., Visser, P. Jelle, Winblad, B., Waldemar, G., and Lawlor, B., “Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe.”, J Alzheimers Dis, vol. 60, no. 1, pp. 201-210, 2017.
J. Toombs, Foiani, M. S., Paterson, R. W., Heslegrave, A., Wray, S., Schott, J. M., Fox, N. C., Lunn, M. P., Blennow, K., and Zetterberg, H., “Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β Concentration.”, J Alzheimers Dis, vol. 56, no. 3, pp. 885-891, 2017.
X. Li, Westman, E., Thordardottir, S., Ståhlbom, A. Kinhult, Almkvist, O., Blennow, K., Wahlund, L. - O., and Graff, C., “The Effects of Gene Mutations on Default Mode Network in Familial Alzheimer's Disease.”, J Alzheimers Dis, vol. 56, no. 1, pp. 327-334, 2017.
V. Bloniecki, Aarsland, D., Blennow, K., Cummings, J., Falahati, F., Winblad, B., and Freund-Levi, Y., “Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 57, no. 2, pp. 387-393, 2017.
M. Carmona-Iragui, Santos, T., Videla, S., Fernández, S., Benejam, B., Videla, L., Alcolea, D., Blennow, K., Blesa, R., Lleo, A., and Fortea, J., “Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1489-1496, 2017.
L. J. C. van Wa van Doorn, Gispert, J. D., H Kuiperij, B., Claassen, J. A. H. R., Arighi, A., Baldeiras, I., Blennow, K., Bozzali, M., Castelo-Branco, M., Cavedo, E., Emek-Savaş, D. D., Eren, E., Eusebi, P., Farotti, L., Fenoglio, C., Ormaechea, J. Fortea, Freund-Levi, Y., Frisoni, G. B., Galimberti, D., Genc, S., Greco, V., Hampel, H., Herukka, S. - K., Liu, Y., Lladó, A., Lleo, A., Nobili, F. M., Oguz, K. K., Parnetti, L., Pereira, J., Picco, A., Pikkarainen, M., de Oliveira, C. Resende, Saka, E., Salvadori, N., Sánchez-Valle, R., Santana, I., Scarpini, E., Scheltens, P., Soininen, H., Tarducci, R., Teunissen, C., Tsolaki, M., Urbani, A., Vilaplana, E., Visser, P. Jelle, Wallin, A. K., Yener, G., Molinuevo, J. L., Meulenbroek, O., and Verbeek, M. M., “Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.”, J Alzheimers Dis, vol. 56, no. 2, pp. 543-555, 2017.
R. Sala-Llonch, Idland, A. - V., Borza, T., Watne, L. Otto, Wyller, T. Bruun, Brækhus, A., Zetterberg, H., Blennow, K., Walhovd, K. Beate, and Fjell, A. Martin, “Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition.”, J Alzheimers Dis, vol. 58, no. 3, pp. 829-840, 2017.
S. E. Berman, Clark, L. R., Rivera-Rivera, L. A., Norton, D., Racine, A. M., Rowley, H. A., Bendlin, B. B., Blennow, K., Zetterberg, H., Carlsson, C. M., Asthana, S., Turski, P., Wieben, O., and Johnson, S. C., “Intracranial Arterial 4D Flow in Individuals with Mild Cognitive Impairment is Associated with Cognitive Performance and Amyloid Positivity.”, J Alzheimers Dis, vol. 60, no. 1, pp. 243-252, 2017.
P. Lewczuk, Lelental, N., Lachmann, I., Holzer, M., Flach, K., Brandner, S., Engelborghs, S., Teunissen, C. E., Zetterberg, H., Molinuevo, J. Luis, Mroczko, B., Blennow, K., Popp, J., Parnetti, L., Chiasserini, D., Perret-Liaudet, A., Spitzer, P., Maler, J. Manuel, and Kornhuber, J., “Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization.”, J Alzheimers Dis, vol. 55, no. 1, pp. 159-170, 2017.
B. F. Darst, Koscik, R. L., Racine, A. M., Oh, J. M., Krause, R. A., Carlsson, C. M., Zetterberg, H., Blennow, K., Christian, B. T., Bendlin, B. B., Okonkwo, O. C., Hogan, K. J., Hermann, B. P., Sager, M. A., Asthana, S., Johnson, S. C., and Engelman, C. D., “Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 473-484, 2017.
K. D. Deters, Risacher, S. L., Kim, S., Nho, K., West, J. D., Blennow, K., Zetterberg, H., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., and Saykin, A. J., “Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease.”, J Alzheimers Dis, vol. 58, no. 4, pp. 1245-1254, 2017.
A. - V. Idland, Wyller, T. Bruun, Støen, R., Eri, L. Magne, Frihagen, F., Ræder, J., Chaudhry, F. Abbas, Hansson, O., Zetterberg, H., Blennow, K., Bogdanovic, N., Brækhus, A., and Watne, L. Otto, “Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium.”, J Alzheimers Dis, vol. 55, no. 1, pp. 371-379, 2017.
P. Johansson, Almqvist, E. G., Bjerke, M., Wallin, A., Johansson, J. - O., Andreasson, U., Blennow, K., Zetterberg, H., and Svensson, J., “Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 59, no. 3, pp. 1017-1026, 2017.
2016
A. M. Racine, Clark, L. R., Berman, S. E., Koscik, R. L., Mueller, K. D., Norton, D., Nicholas, C. R., Blennow, K., Zetterberg, H., Jedynak, B., Bilgel, M., Carlsson, C. M., Christian, B. T., Asthana, S., and Johnson, S. C., “Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1395-1408, 2016.
M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
K. E. Melah, Lu, S. Yuan- Fu, Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., N Dowling, M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., and Bendlin, B. B., “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
N. Lelental, Brandner, S., Kofanova, O., Blennow, K., Zetterberg, H., Andreasson, U., Engelborghs, S., Mroczko, B., Gabryelewicz, T., Teunissen, C., Mollenhauer, B., Parnetti, L., Chiasserini, D., Molinuevo, J. Luis, Perret-Liaudet, A., Verbeek, M. M., Andreasen, N., Brosseron, F., Bahl, J. M. C., Herukka, S. - K., Hausner, L., Frölich, L., Labonte, A., Poirier, J., Miller, A. - M., Zilka, N., Kovacech, B., Urbani, A., Suardi, S., Oliveira, C., Baldeiras, I., Dubois, B., Rot, U., Lehmann, S., Skinningsrud, A., Betsou, F., Wiltfang, J., Gkatzima, O., Winblad, B., Buchfelder, M., Kornhuber, J., and Lewczuk, P., “Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”, J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.
C. - H. Andersson, Hansson, O., Minthon, L., Andreasen, N., Blennow, K., Zetterberg, H., Skoog, I., Wallin, A., Nilsson, S., and Kettunen, P., “A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1353-63, 2016.
J. Spiegel, Pirraglia, E., Osorio, R. S., Glodzik, L., Li, Y., Tsui, W., Louis, L. A. Saint, Randall, C., Butler, T., Xu, J., Zinkowski, R. P., Zetterberg, H., Fortea, J., Fossati, S., Wisniewski, T., Davies, P., Blennow, K., and de Leon, M. J., “Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.”, J Alzheimers Dis, vol. 49, no. 1, pp. 93-100, 2016.
S. M. Hoscheidt, Starks, E. J., Oh, J. M., Zetterberg, H., Blennow, K., Krause, R. A., Gleason, C. E., Puglielli, L., Atwood, C. S., Carlsson, C. M., Asthana, S., Johnson, S. C., and Bendlin, B. B., “Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.”, J Alzheimers Dis, vol. 52, no. 4, pp. 1373-83, 2016.
E. Portelius, Durieu, E., Bodin, M., Cam, M., Pannee, J., Leuxe, C., Mabondzo, A., Oumata, N., Galons, H., Lee, J. Yeol, Chang, Y. - T., Stϋber, K., Koch, P., Fontaine, G., Potier, M. - C., Manousopoulou, A., Garbis, S. D., Covaci, A., Van Dam, D., De Deyn, P., Karg, F., Flajolet, M., Omori, C., Hata, S., Suzuki, T., Blennow, K., Zetterberg, H., and Meijer, L., “Specific Triazine Herbicides Induce Amyloid-β42 Production.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1593-1605, 2016.
2014
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
2012
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.

Pages